Related Experiment Video

Updated: Nov 9, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K

Tepotinib hydrochloride for the treatment of non-small cell lung cancer

Z-X Wu1, J Li2, S Dong3

  • 1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA.

Drugs of Today (Barcelona, Spain : 1998)
|April 14, 2021
PubMed

Insights

Tepotinib is an effective tyrosine kinase inhibitor (TKI) for non-small cell lung cancer (NSCLC) patients with specific mutations. Clinical trials show durable responses, leading to its approval and highlighting its promise for NSCLC treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Non-small cell lung cancer (NSCLC) presents a significant global health challenge with high mortality rates.
  • Tyrosine kinase inhibitors (TKIs) targeting specific molecular pathways are crucial in NSCLC treatment.
  • Mesenchymal-epithelial transition (MET) alterations, particularly METex14 skipping mutations, drive NSCLC progression in a subset of patients.

Purpose of the Study:

  • To review the pharmacological profile, preclinical data, and clinical trial outcomes of tepotinib hydrochloride.
  • To evaluate tepotinib's efficacy and safety as a MET inhibitor for NSCLC.
  • To discuss the future prospects of tepotinib in NSCLC therapy.

Main Methods:

  • Review of published preclinical studies investigating tepotinib's mechanism of action and in vitro/in vivo activity.
  • Analysis of data from Phase II clinical trials assessing tepotinib's efficacy and safety in NSCLC patients with METex14 skipping mutations.
  • Synthesis of information regarding tepotinib's pharmacokinetic and pharmacodynamic properties.

Main Results:

  • Tepotinib demonstrated significant and durable clinical responses in Phase II trials for NSCLC patients with METex14 skipping mutations.
  • The drug's pharmacological profile supports its role as an orally bioavailable MET TKI.
  • Regulatory milestones, including approval in Japan and breakthrough therapy designation in the U.S., underscore tepotinib's clinical value.

Conclusions:

  • Tepotinib represents a promising targeted therapy for a specific population of NSCLC patients.
  • Its efficacy in clinical trials supports its established role in the NSCLC treatment landscape.
  • Further research and clinical evaluation will continue to define tepotinib's optimal use and potential in oncology.
Keywords:
Mesenchymal-epithelial transition (MET) inhibitorsNon-small cell lung cancer (NSCLC)Targeted therapyTepotinib hydrochlorideTyrosine kinase inhibitors

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:31

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

132
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
305
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
273
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
310
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.5K